S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
Is Gold Really Boring? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
3 Reasons This Tech Giant Is Going Back To Highs
Is Gold Really Boring? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
Is Gold Really Boring? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
3 Reasons This Tech Giant Is Going Back To Highs
Is Gold Really Boring? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
Is Gold Really Boring? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
3 Reasons This Tech Giant Is Going Back To Highs
Is Gold Really Boring? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
Is Gold Really Boring? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
3 Reasons This Tech Giant Is Going Back To Highs
Is Gold Really Boring? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
NYSE:HAE

Haemonetics (HAE) Stock Forecast, Price & News

$91.80
+0.46 (+0.50%)
(As of 09/20/2023 ET)
Compare
Today's Range
$91.55
$92.49
50-Day Range
$83.97
$93.49
52-Week Range
$71.63
$95.26
Volume
215,121 shs
Average Volume
254,427 shs
Market Capitalization
$4.66 billion
P/E Ratio
34.64
Dividend Yield
N/A
Price Target
$103.67

Haemonetics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
12.9% Upside
$103.67 Price Target
Short Interest
Bearish
3.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.54
Upright™ Environmental Score
News Sentiment
0.06mentions of Haemonetics in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$671,638 Sold Last Quarter
Proj. Earnings Growth
6.54%
From $3.82 to $4.07 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

443rd out of 962 stocks

Surgical & Medical Instruments Industry

48th out of 96 stocks


HAE stock logo

About Haemonetics (NYSE:HAE) Stock

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

HAE Price History

HAE Stock News Headlines

Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Myriad Genetics' (MYGN) New Deal to Use MRD Testing Platform
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Teleflex (TFX) New Survey Highlights BPH Impact Life Quality
Quest Diagnostics (DGX) to Aid Health Equity With New Pact
Haemonetics (NYSE: HAE)
Globus Medical (GMED) Completes NuVasive Merger Agreement
Are Medical Stocks Lagging Haemonetics (HAE) This Year?
See More Headlines
Receive HAE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Haemonetics and its competitors with MarketBeat's FREE daily newsletter.

HAE Company Calendar

Last Earnings
8/08/2023
Today
9/21/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
Sector
Medical
CUSIP
40502410
Employees
3,034
Year Founded
1971

Price Target and Rating

Average Stock Price Forecast
$103.67
High Stock Price Forecast
$115.00
Low Stock Price Forecast
$88.00
Forecasted Upside/Downside
+12.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$115.40 million
Pretax Margin
13.75%

Debt

Sales & Book Value

Annual Sales
$1.17 billion
Cash Flow
$5.01 per share
Book Value
$16.22 per share

Miscellaneous

Free Float
49,804,000
Market Cap
$4.66 billion
Optionable
Optionable
Beta
0.41

Social Links

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Christopher A. SimonMr. Christopher A. Simon (Age 59)
    CEO, Pres & Director
    Comp: $3.26M
  • Mr. James C. D'Arecca CPA (Age 52)
    CFO, Exec. VP & Financial Officer
    Comp: $1.8M
  • Ms. Anila LingamneniMs. Anila Lingamneni (Age 55)
    Exec. VP & CTO
    Comp: $1.09M
  • Ms. Michelle L. BasilMs. Michelle L. Basil (Age 51)
    Exec. VP, Gen. Counsel & Sec.
    Comp: $1.26M
  • Mr. Josep Lluis Llorens (Age 61)
    Exec. VP of Global Manufacturing & Supply Chain
    Comp: $1.11M
  • Ms. Farris Maryanne Maunsell (Age 48)
    VP, Chief Accounting Officer & Principal Accounting Officer
  • Ms. Olga Guyette
    Sr. Director of Investor Relations
  • Carla Burigatto
    VP of Communications
  • Mr. Rajeev Varma
    Sr. VP of Strategy & Corp. Devel.
  • Ms. Laurie A. MillerMs. Laurie A. Miller (Age 50)
    Sr. VP & Chief HR Officer













HAE Stock - Frequently Asked Questions

Should I buy or sell Haemonetics stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HAE shares.
View HAE analyst ratings
or view top-rated stocks.

What is Haemonetics' stock price forecast for 2023?

6 equities research analysts have issued 12-month target prices for Haemonetics' shares. Their HAE share price forecasts range from $88.00 to $115.00. On average, they anticipate the company's share price to reach $103.67 in the next year. This suggests a possible upside of 12.9% from the stock's current price.
View analysts price targets for HAE
or view top-rated stocks among Wall Street analysts.

How have HAE shares performed in 2023?

Haemonetics' stock was trading at $78.65 at the start of the year. Since then, HAE stock has increased by 16.7% and is now trading at $91.80.
View the best growth stocks for 2023 here
.

Are investors shorting Haemonetics?

Haemonetics saw a increase in short interest in August. As of August 31st, there was short interest totaling 1,580,000 shares, an increase of 21.5% from the August 15th total of 1,300,000 shares. Based on an average daily trading volume, of 290,600 shares, the days-to-cover ratio is currently 5.4 days. Currently, 3.2% of the shares of the stock are short sold.
View Haemonetics' Short Interest
.

When is Haemonetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our HAE earnings forecast
.

How were Haemonetics' earnings last quarter?

Haemonetics Co. (NYSE:HAE) issued its quarterly earnings results on Tuesday, August, 8th. The medical instruments supplier reported $1.05 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.32. The medical instruments supplier earned $311.30 million during the quarter, compared to analyst estimates of $292.74 million. Haemonetics had a trailing twelve-month return on equity of 22.49% and a net margin of 11.21%. Haemonetics's revenue for the quarter was up 19.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.58 EPS.

What guidance has Haemonetics issued on next quarter's earnings?

Haemonetics issued an update on its FY 2024 earnings guidance on Tuesday, August, 8th. The company provided EPS guidance of $3.60-$3.90 for the period, compared to the consensus estimate of $3.59. The company issued revenue guidance of $1.24 billion-$1.27 billion, compared to the consensus revenue estimate of $1.24 billion.

What is Christopher Simon's approval rating as Haemonetics' CEO?

48 employees have rated Haemonetics Chief Executive Officer Christopher Simon on Glassdoor.com. Christopher Simon has an approval rating of 63% among the company's employees. This puts Christopher Simon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Haemonetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), AbbVie (ABBV), Citigroup (C), Align Technology (ALGN), Chipotle Mexican Grill (CMG), Netflix (NFLX) and Pfizer (PFE).

What is Haemonetics' stock symbol?

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

Who are Haemonetics' major shareholders?

Haemonetics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Capital Research Global Investors (13.19%), Shaolin Capital Management LLC (0.00%), Schroder Investment Management Group (1.96%), Geode Capital Management LLC (1.96%), Royce & Associates LP (1.79%) and Fisher Asset Management LLC (1.78%). Insiders that own company stock include Anila Lingamneni, Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Laurie A Miller, Mark W Kroll, Mark W Kroll, Michelle L Basil, Michelle L Basil, Richard J Meelia, Stewart W Strong and William P Mr Burke.
View institutional ownership trends
.

How do I buy shares of Haemonetics?

Shares of HAE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Haemonetics' stock price today?

One share of HAE stock can currently be purchased for approximately $91.80.

How much money does Haemonetics make?

Haemonetics (NYSE:HAE) has a market capitalization of $4.66 billion and generates $1.17 billion in revenue each year. The medical instruments supplier earns $115.40 million in net income (profit) each year or $2.65 on an earnings per share basis.

How many employees does Haemonetics have?

The company employs 3,034 workers across the globe.

How can I contact Haemonetics?

Haemonetics' mailing address is 125 Summer Street, Boston MA, 02110. The official website for the company is www.haemonetics.com. The medical instruments supplier can be reached via phone at (781) 848-7100, via email at gerry.gould@haemonetics.com, or via fax at 781-848-5106.

This page (NYSE:HAE) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -